Advertisement

Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer

Abstract

Aims and background. This paper deals with the clinical significance of the immunohistochemical expression of MAGE-A1, MAGE-A3/4 and NY-ESO-1 antigens in patients with non-small cell lung cancer (NSCLC).
Methods and study design. The study included 80 patients with NSCLC (40 with adenocarcinoma, 40 with squamous cell carcinoma) who had undergone surgery. MAGEA1 and MAGE-A3/4 antigen expression was determined by an immunohistochemical method using the monoclonal antibody 57B, and NY-ESO-1 antigen expression was determined with the addition of the B9.8.1.1 antibody. The expression of these antigens was compared with the clinicopathological features of the tumors and the survival of the patients.
Results. MAGE-A1, MAGE-A3/4 and NY-ESO-1 were expressed in 17.3%, 44.4% and 18.5% of NSCLC patients, respectively. A statistically higher immunohistological expression rate of MAGE-A3/4 was found in squamous cell carcinoma (P >0.001) and a significantly higher amount of tumor necrosis was observed in tumors with MAGE-3 expression (P = 0.001), but no correlation with positive lymph nodes was found. There was a statistically significant correlation between MAGE-A1 expression in adenocarcinoma and the presence of tumor necrosis (P = 0.05). Furthermore, there was a significant correlation between NY-ESO-1 expression and positive lymph nodes in adenocarcinoma, but not in squamous cell carcinoma. No statistically significant difference in patient survival was found with regard to tumor type and the observed histopathological characteristics except tumor size. Statistically significantly better survival was found in the group of patients with adenocarcinomas who had positive expression of MAGE-A3/4 (P = 0.012).
Conclusions. This study demonstrated that the expression of MAGE-A3/4 antigen might be a valuable prognostic factor regarding survival in patients with NSCLC.

Tumori 2014; 100(1): 60 - 68

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1430.15817

Authors

Josip Joachim Grah, Darko Katalinic, Antonio Juretic, Fedor Santek, Miroslav Samarzija

Article History

This article is available as full text PDF.

Download any of the following attachments:

Authors

  • Grah, Josip Joachim [PubMed] [Google Scholar]
    Department of Oncology, Medicine, University Hospital Center (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia
  • Katalinic, Darko [PubMed] [Google Scholar]
    Department of Oncology, Medicine, University Hospital Center (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia
  • Juretic, Antonio [PubMed] [Google Scholar]
    Department of Oncology, Medicine, University Hospital Center (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia
  • Santek, Fedor [PubMed] [Google Scholar]
    Department of Oncology, Medicine, University Hospital Center (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia
  • Samarzija, Miroslav [PubMed] [Google Scholar]
    Department of Pulmonary Medicine, University Hospital Center (KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.